Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment

Evert L. De Beer, Antonio E. Bottone, Jolanda Van Der Velden, Emile E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Crossbridge dynamics underlying the acute and chronic inotropic effects of doxorubicin (Dox) were studied by application of releasing length steps (amplitude, 0.5-10%) to skinned cardiac trabeculae. Acute incubation of trabeculae with 20 μM Dox for 30 min resulted in a decrease of the velocity of unloaded shortening (V(o), from 9.3 ± 1.1 to 7.7 ± 0.7 μm/s, P < .05) and in an increase of the rate of force redevelopment (τ(r) from 56 ± 4 to 65 ± 3 ms, P < .05) in response to step amplitudes ranging from 5 to 10%. In contrast, chronic Dox treatment in rats (2 mg/kg/week for 4 weeks) significantly impaired trabecular crossbridge dynamics after step releases of 0.5%. This was reflected by an increase of all time constants describing tension recovery: τ1, from 10 ± 1 to 14 ± 1 ms; τ2 from 65 ± 6 to 82 ± 6 ms; τ3, from 92 ± 7 to 293 ± 67 ms; P < .05. In addition, V(o) was decreased (from 8.6 ± 0.6 to 6.8 ± 0.3 μm/s, P < .05) and τ(r) was increased (from 67 ± 4 to 89 ± 3 ms; P < .05) in the slack-test. We found that chronic Dox treatment resulted in a shift from the 'high ATPase' α- myosin heavy chain (MHC) isoform toward the 'low-ATPase' β-MHC isoform in the ventricles (control: α-MHC 79 ± 2% and β-MHC 21 ± 2%; Dox, treated: α-MHC 53 ± 2% and β-MHC 47 ± 2%; P < .05). The present results show that acute Dox incubation affects the detachment rate of crossbridges, which leads to a delayed relaxation and an arrest of crossbridges in strongly bound states. In contrast, chronic Dox treatment leads to an impairment of both the attachment and detachment rates in the crossbridge cycle, which may be explained by an altered MHC isoform composition in ventricular myocardium. Interfering with Dox-induced alterations of crossbridge kinetics may provide a new strategy to prevent Dox-associated cardiotoxicity.

Original languageEnglish
Pages (from-to)1152-1157
Number of pages6
JournalMolecular Pharmacology
Volume57
Issue number6
Publication statusPublished - 26 Jun 2000

Cite this

@article{3e5d79dbe9e14efe947c8393312dedfd,
title = "Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment",
abstract = "Crossbridge dynamics underlying the acute and chronic inotropic effects of doxorubicin (Dox) were studied by application of releasing length steps (amplitude, 0.5-10{\%}) to skinned cardiac trabeculae. Acute incubation of trabeculae with 20 μM Dox for 30 min resulted in a decrease of the velocity of unloaded shortening (V(o), from 9.3 ± 1.1 to 7.7 ± 0.7 μm/s, P < .05) and in an increase of the rate of force redevelopment (τ(r) from 56 ± 4 to 65 ± 3 ms, P < .05) in response to step amplitudes ranging from 5 to 10{\%}. In contrast, chronic Dox treatment in rats (2 mg/kg/week for 4 weeks) significantly impaired trabecular crossbridge dynamics after step releases of 0.5{\%}. This was reflected by an increase of all time constants describing tension recovery: τ1, from 10 ± 1 to 14 ± 1 ms; τ2 from 65 ± 6 to 82 ± 6 ms; τ3, from 92 ± 7 to 293 ± 67 ms; P < .05. In addition, V(o) was decreased (from 8.6 ± 0.6 to 6.8 ± 0.3 μm/s, P < .05) and τ(r) was increased (from 67 ± 4 to 89 ± 3 ms; P < .05) in the slack-test. We found that chronic Dox treatment resulted in a shift from the 'high ATPase' α- myosin heavy chain (MHC) isoform toward the 'low-ATPase' β-MHC isoform in the ventricles (control: α-MHC 79 ± 2{\%} and β-MHC 21 ± 2{\%}; Dox, treated: α-MHC 53 ± 2{\%} and β-MHC 47 ± 2{\%}; P < .05). The present results show that acute Dox incubation affects the detachment rate of crossbridges, which leads to a delayed relaxation and an arrest of crossbridges in strongly bound states. In contrast, chronic Dox treatment leads to an impairment of both the attachment and detachment rates in the crossbridge cycle, which may be explained by an altered MHC isoform composition in ventricular myocardium. Interfering with Dox-induced alterations of crossbridge kinetics may provide a new strategy to prevent Dox-associated cardiotoxicity.",
author = "{De Beer}, {Evert L.} and Bottone, {Antonio E.} and {Van Der Velden}, Jolanda and Voest, {Emile E.}",
year = "2000",
month = "6",
day = "26",
language = "English",
volume = "57",
pages = "1152--1157",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. / De Beer, Evert L.; Bottone, Antonio E.; Van Der Velden, Jolanda; Voest, Emile E.

In: Molecular Pharmacology, Vol. 57, No. 6, 26.06.2000, p. 1152-1157.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment

AU - De Beer, Evert L.

AU - Bottone, Antonio E.

AU - Van Der Velden, Jolanda

AU - Voest, Emile E.

PY - 2000/6/26

Y1 - 2000/6/26

N2 - Crossbridge dynamics underlying the acute and chronic inotropic effects of doxorubicin (Dox) were studied by application of releasing length steps (amplitude, 0.5-10%) to skinned cardiac trabeculae. Acute incubation of trabeculae with 20 μM Dox for 30 min resulted in a decrease of the velocity of unloaded shortening (V(o), from 9.3 ± 1.1 to 7.7 ± 0.7 μm/s, P < .05) and in an increase of the rate of force redevelopment (τ(r) from 56 ± 4 to 65 ± 3 ms, P < .05) in response to step amplitudes ranging from 5 to 10%. In contrast, chronic Dox treatment in rats (2 mg/kg/week for 4 weeks) significantly impaired trabecular crossbridge dynamics after step releases of 0.5%. This was reflected by an increase of all time constants describing tension recovery: τ1, from 10 ± 1 to 14 ± 1 ms; τ2 from 65 ± 6 to 82 ± 6 ms; τ3, from 92 ± 7 to 293 ± 67 ms; P < .05. In addition, V(o) was decreased (from 8.6 ± 0.6 to 6.8 ± 0.3 μm/s, P < .05) and τ(r) was increased (from 67 ± 4 to 89 ± 3 ms; P < .05) in the slack-test. We found that chronic Dox treatment resulted in a shift from the 'high ATPase' α- myosin heavy chain (MHC) isoform toward the 'low-ATPase' β-MHC isoform in the ventricles (control: α-MHC 79 ± 2% and β-MHC 21 ± 2%; Dox, treated: α-MHC 53 ± 2% and β-MHC 47 ± 2%; P < .05). The present results show that acute Dox incubation affects the detachment rate of crossbridges, which leads to a delayed relaxation and an arrest of crossbridges in strongly bound states. In contrast, chronic Dox treatment leads to an impairment of both the attachment and detachment rates in the crossbridge cycle, which may be explained by an altered MHC isoform composition in ventricular myocardium. Interfering with Dox-induced alterations of crossbridge kinetics may provide a new strategy to prevent Dox-associated cardiotoxicity.

AB - Crossbridge dynamics underlying the acute and chronic inotropic effects of doxorubicin (Dox) were studied by application of releasing length steps (amplitude, 0.5-10%) to skinned cardiac trabeculae. Acute incubation of trabeculae with 20 μM Dox for 30 min resulted in a decrease of the velocity of unloaded shortening (V(o), from 9.3 ± 1.1 to 7.7 ± 0.7 μm/s, P < .05) and in an increase of the rate of force redevelopment (τ(r) from 56 ± 4 to 65 ± 3 ms, P < .05) in response to step amplitudes ranging from 5 to 10%. In contrast, chronic Dox treatment in rats (2 mg/kg/week for 4 weeks) significantly impaired trabecular crossbridge dynamics after step releases of 0.5%. This was reflected by an increase of all time constants describing tension recovery: τ1, from 10 ± 1 to 14 ± 1 ms; τ2 from 65 ± 6 to 82 ± 6 ms; τ3, from 92 ± 7 to 293 ± 67 ms; P < .05. In addition, V(o) was decreased (from 8.6 ± 0.6 to 6.8 ± 0.3 μm/s, P < .05) and τ(r) was increased (from 67 ± 4 to 89 ± 3 ms; P < .05) in the slack-test. We found that chronic Dox treatment resulted in a shift from the 'high ATPase' α- myosin heavy chain (MHC) isoform toward the 'low-ATPase' β-MHC isoform in the ventricles (control: α-MHC 79 ± 2% and β-MHC 21 ± 2%; Dox, treated: α-MHC 53 ± 2% and β-MHC 47 ± 2%; P < .05). The present results show that acute Dox incubation affects the detachment rate of crossbridges, which leads to a delayed relaxation and an arrest of crossbridges in strongly bound states. In contrast, chronic Dox treatment leads to an impairment of both the attachment and detachment rates in the crossbridge cycle, which may be explained by an altered MHC isoform composition in ventricular myocardium. Interfering with Dox-induced alterations of crossbridge kinetics may provide a new strategy to prevent Dox-associated cardiotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0034049981&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 1152

EP - 1157

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -